BMS has joined forces with uniQure to develop gene therapies for cardiovascular diseases

WASHINGTON - April 7, 2015 - PRLog -- Bristol-Myers Squibb (BMS) will get exclusive access to uniQure’s gene technology platform based on a strategic collaboration between both companies to identify multiple targets in cardiovascular diseases. BMS is expected to make near-term payments of approximately $100 million to uniQure and also purchase shares in the company equaling 4.9% for at least $32 million. BMS will also acquire an additional 5.0% ownership before December 31, 2015, at a 10% premium.

By utilizing uniQure’s proprietary gene therapy program, this joint venture will focus on congestive heart failure which includes restoring the heart’s ability to synthesize S100A1, a calcium sensor and an important regulator of cardiac contractility. uniQure will manufacture all clinical and commercial supplies using its vector technologies and its industrial, proprietary insect-cell based manufacturing platform. BMS will lead development and regulatory activities, cover all research and development costs and assume sole responsibility for commercialization of all products from this collaboration.

“Bristol-Myers Squibb has an excellent and long-standing track record of success in discovering and developing treatments for cardiovascular diseases and in embracing advancing technologies for the treatment of human diseases,” said Carl Decicco, Ph.D., Head of Discovery, R&D, Bristol-Myers Squibb. “Collaborating with uniQure, a clear leader in the field with an innovative and validated gene therapy platform, further strengthens our capability to bring forward transformational new therapeutics for difficult-to-treat diseases, including cardiovascular diseases such as heart failure.”

CANDIDATES WHO WANT TO BREAK INTO PHARMACEUTICAL SALES!

With such industry leaders paving the way on identifying new beneficial therapeutic breakthroughs, they will need both certified and qualified individuals to promote their diversified product portfolio. When industry leaders look for new candidates for sales/marketing positions, they look toward individuals that are industry trained. Companies are looking for people that have the background to promote their product both proficiently and efficiently.

The NAPSRx® is a trade association for pharmaceutical sales reps, sales managers and sales trainers who work in the pharmaceutical industry. NAPSRx® provides Continuing Medical Education to its members as well as CNPR® Certification to candidates who look to enter a pharmaceutical sales career. The CNPR® Program represents a level of industry achievement and a demonstrated knowledge of pharmacology, medical terminology, pharmaceutical selling guidelines, physician selling techniques and industry standards. Upon successful completion of the training each student will receive the Certification Mark of the CNPR®.

Individuals that are interested in becoming a Certified National Pharmaceutical Representative (CNPR) can contact the National Association of Pharmaceutical Sales Representatives(NAPSRx) for more information or visit the website at http://napsronline.org/.